ADMA Biologics
ADMA
23 hedge funds and large institutions have $68.1M invested in ADMA Biologics in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 6 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.33% less ownership
Funds ownership: 78.96% → 78.63% (-0.33%)
12% less funds holding
Funds holding: 26 → 23 (-3)
37% less capital inflows, than outflows
Capital inflows: $1.28M | Capital outflows: $2.05M
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$597K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$534K |
| 3 |
Tower Research Capital (TRC)
New York
|
+$28.7K |
| 4 |
Guggenheim Capital
Chicago,
Illinois
|
+$24.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PointState Capital
New York
|
-$1.64M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$130K |
| 3 |
Goldman Sachs
New York
|
-$107K |
| 4 |
Weiss Multi-Strategy Advisers
New York
|
-$85.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$32K |
ADMA Hedge Fund Activity: Q1 2016 in Review
23 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2016, worth a combined $68.1M — down 0.22% from $68.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ADMA and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was Franklin Resources, adding an estimated $597K. The largest seller was PointState Capital, exiting entirely with an estimated $1.64M sold.
- 23 institutional investors held ADMA Biologics (ADMA) as of Q1 2016, down from 26 in Q4 2015.
- Funds reported $68.1M of ADMA Biologics stock for Q1 2016, down 0.22% quarter-over-quarter.
- 3 funds opened new ADMA Biologics positions in Q1 2016 and 6 closed out, a net change of -3 holders.
- The largest ADMA Biologics buyer in Q1 2016 was Franklin Resources, an estimated $597K added.
- The largest ADMA Biologics seller in Q1 2016 was PointState Capital, an estimated $1.64M sold.
Based on aggregated 13F filings for Q1 2016.